'Wake-Up Pill' Under Study to Treat Patients with Bipolar Disorder

A preliminary study of 85 patients with bipolar disorder shows that a drug used to treat patients with sleep disorders might also control the depressive symptoms associated with bipolar disorder. At least 44 percent of the participants in the study reported improved symptoms, a noteworthy improvement for a disorder in which new treatments are needed, according to the study’s author, Mark Frye, M.D., director of the Mayo Clinic Mood Disorders Clinic and Research Program.

The study appears in the August issue of the American Journal of Psychiatry.

“There are very few treatments for the depressive phase of bipolar disorder and as a result there is an urgent need to evaluate potential new therapeutics,” says Dr. Frye. “Mood stabilizers in general are better at treating mania than depression, but the depressive phase of the illness is far more common. We really need continued research in this area.”

This study was completed in 2005 when Dr. Frye was with the University of California, Los Angeles (UCLA).

Bipolar disorder is characterized by an alternating pattern of emotional highs (mania) and lows (depression). It can range from a mild to severe condition, and there may be periods of normal behavior. (For more information about bipolar disorder, visit www.mayoclinic.com) According to the National Institute of Mental Health, 5.7 million adults in the United States are living with bipolar disorder.

Modafinil, the drug featured in this study, is often referred to in the news media as the “wake-up pill” because it is approved by the Food and Drug Administration (FDA) to treat patients who suffer from excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift
work sleep disorder. During the depressive phase of bipolar disorder the symptoms include
excessive sleepiness and fatigue, so researchers wondered if modafinil could address these symptoms in patients with bipolar disorder.

“This is a placebo-controlled study with real world community impact,” Dr. Frye says. Half of the patients in the study were given modafinil, 100-200 milligrams daily, and the other half were given a placebo over a six-week period. The randomized, double-blind, placebo-controlled trial was conducted at five sites (the University of California, Los Angeles; University of Texas Southwestern; University of Cincinnati; and University of Munich and the University of Freiburg in Germany).

While the trial was small, the 44 percent response rate was greater than that of the placebo group. Forty-four percent said they felt better, while 39 percent said their symptoms were in remission after six weeks. This compares to 23 percent and 18 percent in the control group. Modafinil was not associated with any greater risk of the manic and depressive mood swings associated with bipolar disorder.

How exactly modafinil works to promote wakefulness or improve mood in bipolar disorder is not completely understood. It appears to have an entirely different mechanism of action as compared to other psychostimulants, Dr. Frye says.

Source: Mayo Clinic

Related stories:

Researcher identifies possible genetic causes of borderline personality disorder
According to the National Institute of Mental Health, borderline personality disorder (BPD) is more common than schizophrenia or bipolar disorder and is estimated to affect 2 percent of the population. In a new study, a University of Missouri researcher and Dutch team of research collaborators found that genetic material on chromosome nine was linked to BPD features, a disorder characterized by pervasive instability in moods, interpersonal relationships, self-image and behavior, and can lead to suicidal behavior, substance abuse and failed relationships.
Coerced medication used in psychiatric care despite lack of clinical evidence
Researchers are calling for more studies into the practice of forcing psychiatric patients to take medication, after a research review showed that there have been very few rigorous investigations of the procedure.
Psychiatric disorders common among college-age individuals; few seek treatment
Psychiatric disorders appear to be common among 18- to 24-year-olds, with overall rates similar among those attending or not attending college, according to a report in the December issue of Archives of General Psychiatry. Almost half of college-aged individuals meet criteria for substance abuse, personality disorders or another mental health condition during a one-year period, but only one-fourth of those seek treatment.
14 drugs identified as most urgently needing study for off-label use, Stanford professor says
Physicians and policy-makers know that drugs are frequently prescribed to treat certain diseases despite a lack of FDA approval — a practice known as off-label prescribing. Yet they say the problem is so big they don't know how to begin tackling it.
Bipolar disorder genes, pathways identified
Neuroscientists at the Indiana University School of Medicine have created the first comprehensive map of genes likely to be involved in bipolar disorder, according to research published online Nov. 21 in the American Journal of Medical Genetics.
Patients with depressive disorders or schizophrenia more likely to re-attempt suicide
Men and women who have tried to kill themselves and are suffering from unipolar disorder (major depression), bipolar disorder (manic depression) or schizophrenia are at a very high risk of committing suicide within a year of their first attempt, concludes a study published today on bmj.com.
Methamphetamine abuse linked to underage sex, smoking and drinking
Teens who have never done drugs, but engage in other risky behaviours such as drinking, smoking and being sexually active, are more likely to use crystal meth, medical researchers at the University of Alberta have concluded. Among teens already doing other drugs, those with unstable family environments are most likely to do crystal meth, found the research team led by Dr. Terry Klassen, a professor in the Department of Pediatrics in the Faculty of Medicine & Dentistry.
What do you have in mind? Ethical questions in neuroscience
(PhysOrg.com) -- New methods for examining and influencing brain activity have led to better treatments for disabling neurological and psychiatric diseases, but they also pose ethical questions about their use inside and outside of medicine.

News discussion:

Medicine & Health news